Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAMETA phase 3 trial of savolitinib + durvalumab versus sunitinib in MET-driven papillary renal cell carcinoma
MOH_2021-09-09_010150Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in papillary renal cell carcinoma (PRCC) comparing Savolitinib + Durvalumab, Sunitinib and Durvalumab (3 arms). Planned start Aug 2021; status: not yet recruiting.
02
Drugs
savolitinibdurvalumabsunitinib
03
Conditions
papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on MOH_2021-09-09_010150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-09-09_010150.